Dr. Krystof Bankiewicz, MD, PhD, is a pioneering neurosurgeon and scientist known for his groundbreaking contributions to the field of gene therapy and the treatment of neurological disorders. As the head of several labs, Dr. Bankiewicz has led efforts in the development of novel therapeutic approaches to combat Parkinson’s disease, brain cancer, and other debilitating neurological conditions. His innovative research focuses on the delivery of gene therapy directly to the brain, enabling more precise and effective treatments.
With over 30 years of experience, Dr. Bankiewicz has authored over 230 peer-reviewed publications and holds multiple patents for advanced neurosurgical techniques. His work has been instrumental in advancing the understanding and application of gene therapy in clinical settings, leading to the development of several therapeutic candidates currently in clinical trials.
Dr. Bankiewicz received his MD from Jagiellonian University Medical College in Poland and his PhD from the University of Zurich, Switzerland. He has held prestigious academic and leadership positions, including Professor of Neurosurgery at the University of California, San Francisco (UCSF), where he continues to collaborate with leading scientists and clinicians to push the boundaries of neurological treatments.
He currently serves as a tenured professor at The Ohio State University and holds the Gilbert and Kathryn Mitchell Endowed Chair at The Ohio State University Wexner Medical Center. His visionary leadership and dedication to improving patient outcomes have earned him international recognition as a leader in the field of neurotherapeutics. He has been the co-founder of multiple biotechnology companies including Voyager Therapeutics (IPO), and Brain-Neurotherapeutics (acquired Ask-Bio/Bayer).